2004
DOI: 10.1192/apt.10.5.389
|View full text |Cite
|
Sign up to set email alerts
|

Drug treatment for personality disorders

Abstract: There is some evidence that antidepressants, particularly the selective serotonin reuptake inhibitors and the monoamine oxidase inhibitors, have some benefits in the management of borderline personality disorder, and lesser evidence (partly because of limited trial data) for the benefits of antipsychotic drugs and mood stabilisers. There is not sufficient distinction between the different personality disorders to recommend that any one disorder should be treated by any one drug, and successful treatment is dep… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
36
0
4

Year Published

2009
2009
2020
2020

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 99 publications
(40 citation statements)
references
References 51 publications
0
36
0
4
Order By: Relevance
“…Fourth, and related, the diagnoses have limited clinical utility, not helping practitioners to choose between pharmacological or psychotherapeutic interventions (Sanderson 2002;Tyrer 2004).…”
Section: Critique Of Categorical Systemsmentioning
confidence: 99%
“…Fourth, and related, the diagnoses have limited clinical utility, not helping practitioners to choose between pharmacological or psychotherapeutic interventions (Sanderson 2002;Tyrer 2004).…”
Section: Critique Of Categorical Systemsmentioning
confidence: 99%
“…Positive effects of psychotherapy on the brain is well established (Gabbard, 2005). Medication may also be of value, and antidepressants, mood stabilizers, and/or antipsychotics may facilitate psychotherapy of certain personality disorders such as borderline personality disorder (Tyrer and Bateman, 2004;Paris, 2011). However, it should also be noted that medication may also have negative effects on the brain structure/physiology in patients with personality disorders and may result in acute and/or chronic side effects or dependency (Herpertz et al, 2007).…”
Section: Resistance To Treatment Due To Neurobiological Mechanismsmentioning
confidence: 99%
“…Those changes can be achieved through long-term treatment including psychotherapy, like cognitive-behavioral therapy, which is thought to be particularly beneficial. The APA recommends a combination of psychotherapy and medication as the optimal approach to treat personality disorders (Tyrer and Bateman, 2004). Positive effects of psychotherapy on the brain is well established (Gabbard, 2005).…”
Section: Resistance To Treatment Due To Neurobiological Mechanismsmentioning
confidence: 99%
“…Majority of research attention has focused on BPD and the accumulation of evidence base led to the official treatment guidelines which state that pharmacotherapy is an important adjunct used to treat well-defined target symptoms of the disorder which often fall within three behavioral dimensions -affective dysregulation, impulsive-behavioral dyscontrol, and cognitive-perceptual distortion [6,130]. Nevertheless, our knowledge of how pharmacology can be best applied to personality disorder is limited due to the systematic evidence base being scarce, biased toward BPD, confounded by comorbid psychopathology, limited by small sample sizes, short follow-up, and lack of consensus on core outcome measures [9][10][11]. Consequently, despite the growing evidences to support the use of pharmacotherapy in personality disorders, there are no Food and Drug Administration (FDA) or European Medicines Agency (EMA) -approved medications for treating this disorder and therefore pharmacotherapy for personality disorders remains off-label.…”
Section: Introductionmentioning
confidence: 99%